Clinical Trials
21 trialsNCT03935282 2026-04-15
AH-HA
Wake Forest University Health Sciences
Phase NA Completed
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04209465 2025-04-17
MasterKey-01
Black Diamond Therapeutics, Inc.
Phase 1 Terminated
NCT02431676 2024-08-28
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03665285 2024-03-08
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Completed
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT02001623 2021-12-29
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT03245736 2021-11-04
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen Inc.
Phase 2 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03006887 2021-05-20
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT02552121 2021-04-08
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT03572478 2021-03-09
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Phase 1/2 Terminated
NCT01717391 2019-03-26
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
University of Iowa
Phase 2 Completed
NCT01444456 2017-03-20
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amgen
Completed
NCT01103492 2015-01-05
Treatment of Hemorrhagic Radiation Proctitis Using the Halo System
University Hospitals Cleveland Medical Center
Phase NA Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed